Amanta Healthcare IPO Subscription Status

The Amanta Healthcare IPO saw strong demand, being subscribed 19.63 times on the second day (September 2, 2025, till 5:00 PM).

• Qualified Institutional Buyers (QIBs): 0.53x
• Non-Institutional Investors (NIIs): 36.41x
• Retail Individual Investors (RIIs): 23.35x

In total, the IPO received bids for 13,73,98,114 shares against 70,00,000 shares on offer.

Day-wise subscription:

• Day 1: 4.62x
• Day 2: 19.63x

About Amanta Healthcare Limited

Founded in December 1994, Amanta Healthcare Limited is a leading pharmaceutical company engaged in the development, manufacturing, and marketing of sterile liquid products, primarily parenterals.

Products & Technology

• Manufactures IV fluids, diluents, eye drops, respiratory care solutions, and irrigation solutions.
• Uses advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) for packaging.
• Offers second-aid items and eye lubricants under its medical devices division.

Business Divisions

• National Sales – Distribution network across India.
• International Sales – Partnerships and exports to global markets.
• Product Partnerships – Collaborations with Indian and foreign pharma companies.

Under its own brand, Amanta Healthcare manufactures over 45 generic products, distributed across India through a network of 320 distributors and stockists.

As of March 31, 2025, the company employs 1,718 people.

Financial Performance

• Revenue: ₹276 crore in FY 2025 vs. ₹282 crore in FY 2024 (~2.1% decline)
• Profit After Tax (PAT): ₹10.50 crore in FY 2025 vs. ₹3.63 crore in FY 2024 (~189% growth)

While revenue slightly declined, the company recorded a sharp rise in profitability, reflecting improved operational efficiency and cost management.

Amanta Healthcare IPO GMP

As of Tuesday, September 2, 2025, the Grey Market Premium (GMP) stood at ₹29. This suggests that the IPO shares were trading at ₹155 in the grey market, reflecting a premium over the issue price of ₹126.